With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

TCW Relative Value Large Cap Fund highlighted stocks like Gilead Sciences, Inc. (NASDAQ:GILD), in the third quarter 2024 investor letter. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for ... the market for Gilead Sciences ...

BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...

Nicole Randall, 37, also agreed to forfeit roughly $4 million in proceeds from the sale of the drugs, including four ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.

Also on Thursday, China approved lenacapavir, a long-acting HIV drug made by global biopharmaceutical company Gilead Sciences, according to the administration and the company. The treatment is ...

Merck & Co's Covid-19 antivirals are getting a new lease of life in post-pandemic China, as cat owners seize ... The most popular, GS-441524, developed by Gilead Sciences, hasn't been approved ...